Not a good buy right now for an impatient buyer: the primary trend is still bearish (SMA_200 > SMA_20 > SMA_5) and price is sitting near overhead resistance (R1 ~37.19) after a -2.74% down day.
No Intellectia edge today: neither AI Stock Picker nor SwingMax is signaling a high-conviction entry.
Sentiment is mixed-to-negative: hedge funds have been selling aggressively, while options positioning is bullish but also very expensive (high IV percentile), which often reflects uncertainty ahead of catalysts.
Prefer to wait for either (1) a technical reclaim above ~37.20–37.85 with follow-through, or (2) post-earnings clarity (QDEC 2025 earnings on 2026-02-25 pre-market) before treating this as a "buy now."
Technical Analysis
Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), implying rallies may be sold until the structure improves.
Momentum: MACD histogram is positive (0.0255) and expanding, suggesting a short-term bounce attempt inside a broader downtrend.
RSI: RSI_6 = 72.2 (extended/near overbought on short lookback), which increases the odds of near-term digestion/pullback rather than a clean breakout.
Levels: Pivot ~36.13 is the near-term line in the sand; support at S1 ~35.07 then S2 ~34.42. Resistance at R1 ~37.19 then R2 ~37.84.
Pattern-based forward odds (similar candlesticks): 60% chance of -2.42% next day, +1.38% next week, -4.11% next month (skews against buying aggressively right now).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put/Call OI ratio 0.48 is call-heavy (bullish tilt). Put/Call volume ratio 0.03 is extremely call-dominant today (strong bullish speculation).
Activity: Today’s options volume 660 is 333% of the 30-day average (unusual interest), while open interest is roughly in-line vs its 30-day average (99.7%).
Volatility: 30D IV 48.0 vs historical vol 33.8 (IV > HV), and IV percentile 80.9 (options are expensive). This often coincides with uncertainty into upcoming catalysts (earnings on 2026-02-25).
Takeaway: Options sentiment is bullish, but elevated IV suggests the market is charging a premium for that upside—less attractive for a "must-buy-now" entry in shares without trend confirmation.
Technical Summary
Sell
6
Buy
11
Positive Catalysts
Insiders are buying: buying amount up ~165% over the last month (supportive signal vs current price weakness).
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-25 (pre-market) could reset expectations if results/forward commentary improve.
Short-term momentum improving: MACD positive and expanding suggests a potential near-term rebound attempt.
Options market leaning bullish (call-heavy OI and volume), indicating traders are positioning for upside.
Neutral/Negative Catalysts
implies elevated uncertainty and can coincide with sharp swings around earnings.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $1.377B, +3.15% YoY (modest growth).
Profitability deteriorated materially: Net income -$100M (-80.47% YoY) and EPS -0.44 (-81.97% YoY).
Margins: Gross margin 15.61%, down ~8.61% YoY (pressure on operating quality).
Takeaway: Top-line is growing slightly, but the margin/earnings trend is negative—this reduces conviction to buy immediately without a clear technical reversal or a catalyst-driven inflection.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent direction: price targets have generally been cut across multiple firms (UBS 41→35, Truist 53→40, Baird 45→39, Morgan Stanley 46→39, Wells Fargo 43→32, BofA 40→34, JPM 43→38), reflecting weaker near-term fundamentals.
Rating mix: mostly Neutral/Equal Weight/Underweight with a few Buys (e.g., Truist/Goldman), implying Wall Street is not broadly confident in near-term upside.
Pros (bull case per Street): valuation seen as more "undemanding" after a big pullback; potential for a REIT/cycle improvement later in 2026; earnings may be near a trough.
Cons (bear case per Street): pricing and occupancy pressure, supply-demand imbalances, and risk to 2026 consensus AFFO/EBITDA; multiple analysts suggest "muddle-through" conditions.
Net view: Wall Street tone is cautious—more consistent with "hold/avoid buying right now" than an urgent buy.
Wall Street analysts forecast LINE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LINE is 39.13 USD with a low forecast of 32 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast LINE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LINE is 39.13 USD with a low forecast of 32 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
9 Hold
2 Sell
Hold
Current: 36.740
Low
32
Averages
39.13
High
47
Current: 36.740
Low
32
Averages
39.13
High
47
Scotiabank
Sector Perform
maintain
$37 -> $39
AI Analysis
2026-01-09
Reason
Scotiabank
Price Target
$37 -> $39
AI Analysis
2026-01-09
maintain
Sector Perform
Reason
Scotiabank raised the firm's price target on Lineage to $39 from $37 and keeps a Sector Perform rating on the shares. The firm is updating its price targets for U.S. Cold Storage under its coverage, the analyst tells investors. Scotiabank notes investors should "brace for another tough year," with potential challenges with pricing and occupancy dynamics.
UBS
Michael Goldsmith
Neutral
downgrade
$41 -> $35
2026-01-08
Reason
UBS
Michael Goldsmith
Price Target
$41 -> $35
2026-01-08
downgrade
Neutral
Reason
UBS analyst Michael Goldsmith lowered the firm's price target on Lineage to $35 from $41 and keeps a Neutral rating on the shares. 2026 is expected to mark a pivotal REIT turnaround, with forecast total returns of 9%-11% driven by improving macro conditions, attractive valuations, easing supply pressures, and a more stable political backdrop, the analyst tells investors in a research note. The outlook points to a bifurcated year with defensiveness in the first half of 2026 and stronger catalysts in the second half, favoring Healthcare, Shopping Centers, and Coastal Apartments, UBS says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LINE
